GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: compound 1 [PMID: 29148806] | LJN452
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Tropifexor (LJN452) is a potent non-bile acid  agonist of the ligand-activated nuclear farnesoid X receptor (FXR) [1] that is being developed by Novartis.
                                    
                                   Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖ | 
 | |||||||||||||||||||||||||||||||||||
| References | 
| 1. Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB, Mutnick D, Bursulaya B, Schmeits J, Wu X et al.. (2017) Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem, 60 (24): 9960-9973. [PMID:29148806] |